Introduction
============

Because of the decreases in the incidence of thyroid cancer, the annual cancer incidence has decreased in Korea after 2011 following a steady increase \[[@b1-crt-2017-096]\]. However, cancer is still a major public health problem in Korea. Radiation therapy (RT) is an eﬀective and widespread method for treating cancer in conjunction with surgery and chemotherapy. RT is required in at least 45%-55% of newly diagnosed cancer cases \[[@b2-crt-2017-096]\]. A steady rise in the number of patients with cancer has increased the demand for RT in Korea. As we have reported previously \[[@b3-crt-2017-096],[@b4-crt-2017-096]\], the number of patients with cancer needing RT has steadily increased over the 5 years between 2009 and 2013.

In the present study, we analyzed the claims data from the Health Insurance Review and Assessment Service (HIRA) to estimate the clinical utilization of RT in the 2011-2015 period.

Materials and Methods
=====================

We analyzed open claims data from the HIRA. The analysis methods using claims data from the HIRA are described in detail in a previous study \[[@b4-crt-2017-096]\]. The customized source population criteria for this study are shown in [Table 1](#t1-crt-2017-096){ref-type="table"}. In our previous study \[[@b3-crt-2017-096]\], type of healthcare facility included tertiary and secondary hospitals. However, in this study, primary and sanatorium hospitals were also included. In addition, information about patriots and veterans affairs' insurance expenditure by the government, which were not included in the previous study, were also included in this study. The source population consisted of all patients who had any of the International Classification of Diseases 10th revision cancer diagnoses (C00-C97) and those with diagnostic codes D00-D48 (including carcinoma *in situ* or benign neoplasms), who were also associated with at least one of the procedure codes related to RT treatment \[[@b3-crt-2017-096]\]. The detailed methods of categorization for diagnostic codes are described in a previous study \[[@b3-crt-2017-096]\].

We analyzed the claims data from the HIRA in order to identify the total number of patients who underwent RT, and the number of patients who received RT by primary cancer diagnosis, sex, and age group between 2011 and 2015 in Korea. In addition, through the classification of the procedure codes related to RT \[[@b3-crt-2017-096]\], we estimated the total number of patients who received specific RT modalities, including brachytherapy, intensity-modulated radiation therapy (IMRT), stereotactic radiation therapy (SRT), and proton therapy. Considering the annual cancer incidence \[[@b1-crt-2017-096]\], the percentage of patients who underwent RT was calculated. We also analyzed the geographic differences for the number of patients who received RT. The number of patients was based on the location of the healthcare facilities.

Results
=======

The total number of patients who received RT in 2011, 2012, 2013, 2014, and 2015 were 54,810, 59,435, 61,839, 64,062, and 66,183, respectively ([Fig. 1](#f1-crt-2017-096){ref-type="fig"}). Among them, the total numbers of male and female patients were 24,946/29,864 in 2011, 27,211/32,224 in 2012, 28,111/33,728 in 2013, 29,312/34,750 in 2014, and 30,266/35,917 in 2015 ([Fig. 2](#f2-crt-2017-096){ref-type="fig"}). The absolute number of cancer patients who received RT and the cancer incidence from 2011 to 2014 are shown in [Fig. 3](#f3-crt-2017-096){ref-type="fig"}. The utilization rate of RT in cancer patients has also increased steadily over the same period from 25% to 30%. Because Korea's cancer incidence in 2015 has not been reported yet, the utilization rate of RT in 2015 could not be calculated.

The distribution of patients who received RT by cancer diagnosis between 2011 and 2015 is shown in [Table 2](#t2-crt-2017-096){ref-type="table"}. The five cancers that were most frequently treated with RT between 2011 and 2012 were breast, lung, colorectal, liver, and uterine cervical cancers. However, the fifth most common cancer treated with RT that replaced uterine cervical cancer in 2013 was prostate cancer ([Fig. 4A](#f4-crt-2017-096){ref-type="fig"}). The five most common types of cancer among the male patients were lung, liver, prostate, colorectal, and esophageal cancers, while the incidence of colorectal cancer showed a decreasing trend ([Fig. 4B](#f4-crt-2017-096){ref-type="fig"}). Among female patients, the five most common types were breast, lung, uterine cervical, colorectal, and uterine corpus cancers, while the incidence of colorectal and uterine cervix cancer showed a decreasing trend ([Fig. 4C](#f4-crt-2017-096){ref-type="fig"}).

Breast cancer and carcinoma *in situ* of breast patients accounted for nearly 30% of the total patients who underwent RT, and for approximately half of the female patients ([Table 2](#t2-crt-2017-096){ref-type="table"}). The diseases with code 'D' made up 7% of the total patients treated with RT ([Fig. 1](#f1-crt-2017-096){ref-type="fig"}).

The utilization rates of RT in the 10 most common cancers in Korea \[[@b1-crt-2017-096]\] are shown in [Fig. 5](#f5-crt-2017-096){ref-type="fig"}. The utilization rate of RT increased significantly between 2011 and 2014 for breast (from 85% to 90%), lung (from 41% to 45%), liver (from 18% to 25%), and prostate cancer (from 22% to 27%).

The distribution of patients who received RT in 2015 based on cancer diagnosis and age group is shown in [Table 3](#t3-crt-2017-096){ref-type="table"}. The most common cancer was that of the central nervous system for patients aged 20 years or less, while breast cancer was the most common cancer in patients aged 30-50 years, and lung cancer was the most common cancer in patients aged 60 years or more. Similar trends were observed for previous years.

The distribution of patients who received RT with specific modalities is shown in [Table 4](#t4-crt-2017-096){ref-type="table"}. The use of advanced RT modalities like IMRT, SRT, and proton therapy are steadily increasing every year.

[Table 5](#t5-crt-2017-096){ref-type="table"} shows the distribution of patients who received RT from 2011 to 2015 in Korea for each prefecture. The population of each prefecture in 2015 is shown as a representative value \[[@b5-crt-2017-096]\]. The number of patients has steadily increased every year in all prefectures. More than half of cancer patients (64%) were treated with RT in the capital area (Seoul, Gyeonggi, and Incheon).

Discussion
==========

We analyzed the clinical utilization of RT between 2011 and 2015 in Korea using claims data from the HIRA. The total number of patients who underwent RT has increased by 3%-8% per year between 2011 and 2015 ([Fig. 1](#f1-crt-2017-096){ref-type="fig"}). As shown in [Fig. 3](#f3-crt-2017-096){ref-type="fig"}, the annual cancer incidence in Korea has slowed after increasing until 2011 \[[@b1-crt-2017-096]\], and it decreased in 2014 compared with 2013. However, the number of cancer patients who underwent RT increased annually during the same period ([Fig. 3](#f3-crt-2017-096){ref-type="fig"}). This antithetical pattern seemingly stems from a decrease in the total cancer incidence due to a decrease in the thyroid cancer incidence in recent years in Korea \[[@b1-crt-2017-096]\]. As shown in [Fig. 5](#f5-crt-2017-096){ref-type="fig"}, because the role of external beam RT in well-differentiated thyroid cancer remains controversial \[[@b6-crt-2017-096]\], the decreasing incidence of thyroid cancer does not affect the utilization of RT in cancer patients.

While the numbers of breast, lung, and prostate cancers being treated with RT has increased every year, the numbers of colorectal and uterine cervix cancer treated with RT have not shown any increase ([Fig. 4](#f4-crt-2017-096){ref-type="fig"}). These trends of RT for these cancers have some correlation with the increasing and decreasing trends in the incidence of these cancers ([Fig. 5](#f5-crt-2017-096){ref-type="fig"}). Interestingly, liver cancer has shown a significant increase in the number of RT patients ([Figs. 4](#f4-crt-2017-096){ref-type="fig"} and [5](#f5-crt-2017-096){ref-type="fig"}) although the incidence of liver cancer has been the same or has slightly decreased every year in Korea \[[@b1-crt-2017-096]\]. The increase of RT for patients with liver cancer seems to have a correlation with the remarkable increase of utilization rate of RT ([Fig. 5](#f5-crt-2017-096){ref-type="fig"}). This trend may be because recently many studies have reported good clinical outcomes for hepatocellular carcinoma patients receiving high dose radiation in Korea using advanced RT technologies, including IMRT, SRT, and image guided radiotherapy \[[@b7-crt-2017-096]-[@b12-crt-2017-096]\]. Furthermore, the Korean Practice Guidelines for the Management of Hepatocellular Carcinoma recommend RT for inoperable hepatocellular carcinoma patients \[[@b13-crt-2017-096]\].

Although the percentage of cancer patients who underwent RT increased from 25% to 30% during these 5 years ([Fig. 3](#f3-crt-2017-096){ref-type="fig"}), the clinical utilization rate of RT in Korea seems to be lower than of the estimated optimal utilization rate of developed or developing countries (47%-56%) \[[@b14-crt-2017-096]-[@b16-crt-2017-096]\]. However, recently Mackillop et al. \[[@b17-crt-2017-096]\] criticized the overestimation of the optimal RT utilization rate in the previous reports and reported that optimal utilization rate is 34% considering the conditions of optimal access to RT. Because the study estimated the optimal utilization rate of RT in Korea under conditions of access to RT of Korea was not reported yet, whether 30% of RT utilization in Korea is appropriate is debatable. Nevertheless, the incidence of breast, lung, and prostate cancers that account for over 50% of RT patients is showing an increasing trend every year \[[@b1-crt-2017-096]\]. Therefore, the clinical utilization rate of RT among cancer patients in Korea is expected to continue to rise.

There is an overlap in years between the present and a previous study \[[@b3-crt-2017-096]\]; however, the number of patients who underwent RT are different between the two studies during the same period. Compared to the previous study, annually, an additional 200-300 patients underwent RT between 2011 and 2013. This difference might be because additional healthcare information that was not included in the previous study was integrated in the present study, such as information from primary and sanatorium hospitals and patriots and veterans affairs' insurance expenditure by the government. Besides, there is lately (after 1 or more years) registered claims data in HIRA.

In terms of RT modalities, the number of cases receiving SRT has steadily increased over the last 5 years and it was notably increased especially in 2015. In 2015, the national health insurance coverage of SRT was expanded from only cranio-spinal tumors and inoperable lung cancer to whole body tumors. Similar to SRT, notable increases in the use of IMRT and proton therapy are expected in 2016 because national health insurance coverage of IMRT and proton therapy has been expanded in the second half of 2015. In addition, a second proton therapy center in Korea started operating in 2016 \[[@b18-crt-2017-096]\]. However, it should be kept in mind that the claims data from the HIRA only included data of the insured cases and the number of uninsured treatments could not be recorded. Therefore, the actual number of patients who received SRT, IMRT, and proton therapy are expected to be higher than the reported number.

In 2015, the population of Seoul was 19.5% of Korea's population; however, nearly half of the patients (43.9%) treated with RT were treated in Seoul ([Table 5](#t5-crt-2017-096){ref-type="table"}). If we assume that the optimal rate of RT patients is equal to the percentage of population in each prefecture, Seoul had 2.25 fold of RT patients and Chungbuk had 0.35 fold of RT patients. This phenomenon of concentration in Seoul therefore seems very extreme. To explain this severe disproportion between regions, we need to analyze the infrastructure of RT in Korea. However, unfortunately, no such study has been published after 2007 \[[@b19-crt-2017-096]\]. We are preparing for the report about the status of the infrastructure of radiotherapy in Korea (2015).

The total number of patients who underwent RT increased steadily from 2011 to 2015 in Korea. The utilization rate of RT in cancer patients is also increasing. These trends are expected to continue because the incidences of breast and lung cancers with treatment heavily dependent on RT are also experiencing a rising trend in Korea.
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###### 

Customized source population

  List                          Criteria
  ----------------------------- ---------------------------------------------------------------------------------------------------
  Treatment period              1 Jan 2011-31 Dec 2015
  Type of healthcare facility   Tertiary, secondary, primary, sanatorium
  Diagnostic code               C00-C97, D00-D48
  Type of insurance             Health insurance, medical aid, patriots and veterans affairs' insurance expenditure by government
  Hospital region               National
  Sex                           Male, female
  Age                           All ages

###### 

Distribution of cancer patients who underwent radiation therapy based on primary diagnosis between 2011 and 2015 in Korea

  Category                            Primary diagnosis (diagnostic code)   Year^[a)](#tfn1-crt-2017-096){ref-type="table-fn"}^                              
  ----------------------------------- ------------------------------------- ----------------------------------------------------- -------- -------- -------- --------
  Breast                              (C50)                                 13,765                                                15,059   15,766   16,549   17,302
  Gastrointestinal                    Colorectum (C18-C20)                  5,054                                                 5,048    4,920    4,901    4,898
                                      Liver (C22)                           3,027                                                 3,446    3,641    3,679    4,112
                                      Esophagus (C15)                       1,250                                                 1,335    1,380    1,397    1,472
                                      Stomach (C16)                         1,070                                                 1,048    1,026    992      1,013
                                      Pancreas (C25)                        782                                                   942      906      948      998
                                      Gallbladder and biliary (C23-C24)     778                                                   856      879      954      985
                                      Anus (C21)                            193                                                   213      211      203      199
                                      Small bowel (C17)                     42                                                    39       43       35       32
                                      Other (C26)                           4                                                     5        3        3        3
                                      Subtotal                              12,200                                                12,932   13,009   13,112   13,712
  Thoracic                            Lung (C34)                            8,991                                                 9,425    10,187   10,846   10,863
                                      Thymus (C37)                          258                                                   238      249      307      323
                                      Mediastinum (C38)                     41                                                    44       48       47       54
                                      Trachea (C33)                         16                                                    18       16       22       25
                                      Other (C39)                           4                                                     3        2        1        1
                                      Subtotal                              9,310                                                 9,728    10,502   11,223   11,266
  Head and neck                       Larynx (C32)                          773                                                   884      964      912      903
                                      Oropharynx (C01, C09-C10)             509                                                   615      595      621      619
                                      Oral cavity (C02-C06)                 500                                                   601      588      605      632
                                      Nasopharynx (C11)                     414                                                   489      488      488      516
                                      Salivary gland (C07-C08)              298                                                   346      347      398      374
                                      Hypopharynx (C12-C13)                 354                                                   394      352      437      395
                                      Paranasal sinus (C31)                 149                                                   166      145      179      166
                                      Nasal cavity (C30)                    93                                                    129      110      128      142
                                      Eye and orbit (C69)                   44                                                    54       51       41       58
                                      Lip (C00)                             11                                                    8        13       9        18
                                      Other (C14)                           19                                                    20       14       16       17
                                      Subtotal                              3,164                                                 3,706    3,667    3,834    3,840
  Gynecologic                         Uterine cervix (C53)                  2,453                                                 2,481    2,540    2,425    2,466
                                      Uterine corpus (C54-C55)              635                                                   724      741      810      813
                                      Ovary and tube (C56)                  217                                                   204      247      248      258
                                      Vagina and vulva (C51-C52)            111                                                   111      100      90       122
                                      Other (C57-C58)                       15                                                    14       12       9        11
                                      Subtotal                              3,431                                                 3,534    3,640    3,582    3,670
  Genitourinary                       Prostate (C61)                        1,952                                                 2,451    2,577    2,634    2,778
                                      Ureter and bladder (C66-C67)          498                                                   484      531      608      602
                                      Kidney (C64-C65)                      443                                                   422      445      454      525
                                      Penis and testis (C60, C62-C63)       65                                                    57       66       57       62
                                      Other (C68)                           11                                                    14       12       18       19
                                      Subtotal                              2,969                                                 3,428    3,631    3,771    3,986
  CNS                                 Brain (C70-C71)                       1,388                                                 1,513    1,567    1,623    1,605
                                      Spinal cord (C72)                     60                                                    61       52       48       47
                                      Other (C47)                           45                                                    36       52       32       46
                                      Subtotal                              1,493                                                 1,610    1,671    1,703    1,698
  Lymphoma                            Non-Hodgkin\'s lymphoma (C82-C88)     1,169                                                 1,322    1,321    1,389    1,493
                                      Hodgkin\'s disease (C81)              98                                                    108      91       93       100
                                      Other (C96)                           22                                                    23       21       30       33
                                      Subtotal                              1,289                                                 1,453    1,433    1,512    1,626
  Soft tissue                         (C46, C49)                            545                                                   581      631      648      715
  Mesothelioma                        (C45)                                 14                                                    19       18       19       29
  Myeloma and plasmacytoma            (C90)                                 316                                                   414      442      450      459
  Thyroid                             (C73)                                 354                                                   381      357      360      309
  Leukemia                            (C91-C95)                             359                                                   353      351      411      396
  Skin                                (C44)                                 244                                                   287      264      284      279
  Malignant melanoma                  (C43)                                 215                                                   209      225      244      241
  Primary bone and cartilage          (C40-C41)                             213                                                   219      170      206      223
  Endocrine                           (C74-C75)                             56                                                    72       93       101      104
  Unknown primary                     (C48, C76-C80, C97)                   878                                                   1,070    1,239    1,287    1,420
  Total No. of cancer patients        \-                                    50,815                                                55,055   57,109   59,296   61,275
  Carcinoma *in situ* of the breast   (D05)                                 1,388                                                 1,653    1,918    1,912    2,062
  Benign neoplasm of meninges         (D32)                                 1,022                                                 960      1,041    1,112    1,032
  Benign neoplasm of CNS              (D33)                                 726                                                   750      744      694      713
  Benign neoplasm of endocrine        (D34-D35)                             229                                                   283      304      319      308
  Other D code diseases               (D00-D04, D06-D31, D36-D48)           630                                                   734      723      729      793
  Total D code patients               \-                                    3,995                                                 4,380    4,730    4,766    4,908
  Total                               \-                                    54,810                                                59,435   61,839   64,062   66,183

CNS, central nervous system.

Number of patients who received radiation therapy.

###### 

The number of patients who underwent radiation therapy by cancer diagnosis and age group in Korea (2015)

  Category                            Primary diagnosis                   Age group^[a)](#tfn2-crt-2017-096){ref-type="table-fn"}^                                               
  ----------------------------------- ----------------------------------- ---------------------------------------------------------- ------- -------- -------- -------- -------- --------
  Breast                              Breast (C50)                        114                                                        1,614   5,949    5,908    2,761    956      17,302
  Gastrointestinal                    Colorectum (C18-C20)                13                                                         140     563      1,330    1,376    1,476    4,898
                                      Liver (C22)                         10                                                         89      447      1,332    1,326    908      4,112
                                      Esophagus (C15)                     0                                                          2       50       328      498      594      1,472
                                      Stomach (C16)                       9                                                          66      151      279      258      250      1,013
                                      Pancreas (C25)                      2                                                          16      65       273      340      302      998
                                      Gallbladder and biliary (C23-C24)   0                                                          8       58       237      347      335      985
                                      Anus (C21)                          3                                                          0       16       52       49       79       199
                                      Small bowel (C17)                   0                                                          3       0        10       12       7        32
                                      Other (C26)                         0                                                          0       0        1        2        0        3
                                      Subtotal                            37                                                         324     1,350    3,842    4,208    3,951    13,712
  Thoracic                            Lung (C34)                          14                                                         124     571      2,232    3,632    4,290    10,863
                                      Thymus (C37)                        9                                                          26      71       86       79       52       323
                                      Mediastinum (C38)                   14                                                         4       8        10       11       7        54
                                      Trachea (C33)                       1                                                          1       5        4        7        7        25
                                      Other (C39)                         0                                                          0       0        0        1        0        1
                                      Subtotal                            38                                                         155     655      2,332    3,730    4,356    11,266
  Head and neck                       Larynx (C32)                        0                                                          5       32       204      344      318      903
                                      Oropharynx (C01, C09-C10)           2                                                          7       58       229      211      112      619
                                      Oral cavity (C02-C06)               15                                                         36      77       172      166      166      632
                                      Nasopharynx (C11)                   21                                                         44      109      162      112      68       516
                                      Salivary gland (C07-C08)            21                                                         23      52       100      103      75       374
                                      Hypopharynx (C12-C13)               0                                                          1       11       85       140      158      395
                                      Paranasal sinus (C31)               3                                                          3       28       42       43       47       166
                                      Nasal cavity (C30)                  4                                                          15      20       37       26       40       142
                                      Eye and orbit (C69)                 7                                                          3       7        15       11       15       58
                                      Lip (C00)                           0                                                          0       2        5        3        8        18
                                      Other (C14)                         1                                                          1       0        3        6        6        17
                                      Subtotal                            74                                                         138     396      1,054    1,165    1,013    3,840
  Gynecologic                         Uterine cervix (C53)                24                                                         274     539      702      440      487      2,466
                                      Uterine corpus (C54-C55)            9                                                          24      129      339      213      99       813
                                      Ovary and tube (C56)                1                                                          13      40       98       69       37       258
                                      Vagina and vulva (C51-C52)          0                                                          2       12       28       21       59       122
                                      Other (C57-C58)                     0                                                          1       1        3        5        1        11
                                      Subtotal                            34                                                         314     721      1,170    748      683      3,670
  Genitourinary                       Prostate (C61)                      1                                                          0       18       257      918      1,584    2,778
                                      Ureter and bladder (C66-C67)        1                                                          4       31       94       145      327      602
                                      Kidney (C64-C65)                    11                                                         14      56       141      156      147      525
                                      Penis and testis (C60, C62-C63)     12                                                         14      7        12       7        10       62
                                      Other (C68)                         0                                                          2       2        1        4        10       19
                                      Subtotal                            25                                                         34      114      505      1,230    2,078    3,986
  CNS                                 Brain (C70-C71)                     250                                                        186     264      391      304      210      1,605
                                      Spinal cord (C72)                   15                                                         5       7        6        8        6        47
                                      Other (C47)                         9                                                          12      7        7        6        5        46
                                      Subtotal                            274                                                        203     278      404      318      221      1,698
  Lymphoma                            Non-Hodgkin\'s lymphoma (C82-C88)   78                                                         128     220      361      331      375      1,493
                                      Hodgkin\'s disease (C81)            36                                                         19      10       15       5        15       100
                                      Other (C96)                         5                                                          8       8        8        1        3        33
                                      Subtotal                            119                                                        155     238      384      337      393      1,626
  Soft tissue                         (C46, C49)                          75                                                         73      103      157      135      172      715
  Mesothelioma                        (C45)                               0                                                          0       3        8        12       6        29
  Myeloma and plasmacytoma            (C90)                               1                                                          5       43       113      163      134      459
  Thyroid                             (C73)                               3                                                          3       24       75       82       122      309
  Leukemia                            (C91-C95)                           138                                                        54      85       69       34       16       396
  Skin                                (C44)                               5                                                          11      14       40       53       156      279
  Malignant melanoma                  (C43)                               3                                                          8       31       60       73       66       241
  Primary bone and cartilage          (C40-C41)                           58                                                         23      28       39       34       41       223
  Endocrine                           (C74-C75)                           50                                                         11      4        24       7        8        104
  Unknown primary                     (C48, C76-C80, C97)                 20                                                         53      168      377      429      373      1,420
  Total No. of cancer patients                                            1,068                                                      3,178   10,204   16,561   15,519   14,745   61,275
  Carcinoma *in situ* of the breast   (D05)                               18                                                         184     799      661      323      77       2,062
  Benign neoplasm of meninges         (D32)                               10                                                         36      161      319      266      240      1,032
  Benign neoplasm of CNS              (D33)                               53                                                         65      136      208      148      103      713
  Benign neoplasm of endocrine        (D34-D35)                           19                                                         41      71       84       60       33       308
  Other D code diseases               (D00-D04, D06-D31, D36-D48)         88                                                         75      124      189      176      141      793
  Total D code patients                                                   188                                                        401     1,291    1,461    973      594      4,908
  Total                                                                   1,256                                                      3,579   11,495   18,022   16,492   15,339   66,183

CNS, central nervous system.

Number of patients who received radiation therapy.

###### 

Distribution of patients who received radiation therapy according to specific radiation therapy modalities between 2011 and 2015 in Korea

  Radiation therapy modality              Year^[a)](#tfn3-crt-2017-096){ref-type="table-fn"}^                                                
  --------------------------------------- ----------------------------------------------------- -------------- -------------- -------------- ---------------
  Brachytherapy                           1,421 (2.6)                                           1,421 (2.4)    1,404 (2.3)    1,255 (2.0)    1,247 (1.9)
  Intensity-modulated radiation therapy   6,250 (11.4)                                          6,372 (10.7)   6,698 (10.8)   7,022 (11.0)   8,397 (12.7)
  Stereotactic radiation therapy          3,122 (5.7)                                           6,670 (11.2)   6,772 (11.0)   7,648 (11.9)   12,228 (18.5)
  Proton radiation therapy                25 (0.0)                                              50 (0.1)       33 (0.1)       34 (0.1)       158 (0.2)

Values are presented as number (%).

Percentage of the number of specific radiation therapy modalities over the total number of radiotherapy in each year.

###### 

Demographic data of patients who received radiation therapy between 2011 and 2015 in Korea for each prefecture

  Prefecture                Population (2015) \[[@b5-crt-2017-096]\], ×10^3^ (%)   Year                                                            
  ------------------------- ------------------------------------------------------ --------------- --------------- --------------- --------------- ---------------
  Seoul                     9,860 (19.5)                                           24,713 (45.1)   26,996 (45.4)   27,458 (44.4)   28,303 (44.2)   29,085 (43.9)
  Gyeonggi, Incheon         15,284 (30.2)                                          10,651 (19.4)   11,543 (19.4)   12,228 (19.8)   12,859 (20.1)   13,680 (20.7)
  Gangwon                   1,506 (3.0)                                            1,308 (2.4)     1,422 (2.4)     1,365 (2.2)     1,406 (2.2)     1,501 (2.3)
  Chungbuk                  1,561 (3.1)                                            654 (1.2)       684 (1.2)       683 (1.1)       696 (1.1)       742 (1.1)
  Chungnam, Daejeon         3,822 (7.5)                                            2,548 (4.6)     2,822 (4.7)     3,029 (4.9)     3,047 (4.7)     3,166 (4.8)
  Jeonbuk                   1,798 (3.5)                                            1,299 (2.4)     1,334 (2.2)     1,366 (2.2)     1,466 (2.3)     1,393 (2.1)
  Jeonnam, Gwangju          3,274 (6.5)                                            2,812 (5.1)     3,024 (5.1)     3,119 (5.0)     3,195 (5.0)     3,359 (5.1)
  Gyeongbuk, Daegu          5,097 (10.1)                                           4,062 (7.4)     4,388 (7.4)     4,702 (7.6)     4,922 (7.7)     4,926 (7.4)
  Gyeongnam, Busan, Ulsan   7,827 (15.5)                                           6,393 (11.7)    6,774 (11.4)    7,429 (12.0)    7,652 (11.9)    7,802 (11.8)
  Jeju                      587 (1.1)                                              420 (0.7)       448 (0.8)       460 (0.8)       516 (0.8)       529 (0.8)
  Total                     50,616 (100)                                           54,810 (100)    59,435 (100)    61,839 (100)    64,062 (100)    66,183 (100)

Values are presented as number (%).
